BiotechTube

ASP1585

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Conditions

Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

Trial Timeline

Jan 1, 2008 → Jun 1, 2008

NCT ID
NCT02753894

About ASP1585

ASP1585 is a phase 2 stage product being developed by Astellas Pharma for Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02753894. Target conditions include Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT02531204Phase 1Completed
NCT01742611Phase 3Completed
NCT01017276Phase 3Completed
NCT00892749Phase 3Completed
NCT02753894Phase 2Completed

Competing Products

20 competing products in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25